Media Coverage header image

Media Coverage

Advanced Search
  • 09162018
    60 Minutes

    As we first reported last May, Holmes founded the start-up Theranos and boasted her technology could take a pin-prick worth of blood from the finger and perform hundreds of laboratory tests. It was, she claimed, "the most important thing humanity has ever built." At its zenith, Theranos was worth nearly $10 billion and Elizabeth Holmes became the youngest, self-made, female billionaire in the world. Today, she and her company's one-time president stand criminally charged by the U.S. government of perpetrating a "multi-million dollar scheme" to defraud investors, doctors and patients. Elizabeth Holmes built her company Theranos on this invention she named the Edison. A miniaturized blood analyzer that would disrupt the $60 billion lab testing industry dominated by giants LabCorp and Quest Diagnostics.

  • 09122018
    STAT

    Although more than half of Americans misuse prescription drugs, the percentage that did so has held steady for four consecutive years, according to a new analysis. Meanwhile, though, there has also been a surge in the use of illicit drugs and medicines obtained without a prescription among patients being treated for substance use disorders.

  • 09102018
    ESPN

    The countless drops of sweat covering their drenched bodies are indicative of the hard work put in by the New York Giants throughout the hot and humid summer. Those same droplets were also analyzed and examined to help individual performance. The Giants used a new sweat test this year to make sure their players were properly hydrated and prepared for the rigors of summer. It should continue to help them throughout the season. It’s not a completely new idea, just a refined version of a sweat test. There are other teams using different variations of this new patch the Giants had analyzed by Quest Diagnostics as part of their Blueprint for Athletes program. This iteration is easier to implement and is believed to be more effective than the previous processes they have tried over the past few years. The hope is that its benefits can stretch throughout the year and provide even the slightest of competitive advantages.

  • 09072018
    MedPage Today

    Prescription data alone underestimated how many patients combined opioids and benzodiazepines, an analysis of Quest Diagnostics drug test data indicated. Among a selected sample of patients whose drug test indicated concurrent benzodiazepine and opioid use, 64% had at least one benzodiazepine or opioid that was not prescribed, according to Quest researcher Leland McClure, PhD, and colleagues in a poster presentation at the 2018 PAINWeek conference.

  • 09072018
    BusinessWire

    Genomic Vision, a company specializing in the development of diagnostic tests for the early detection of cancers and hereditary diseases, and applications for life sciences research, today announces the second payment from its collaboration with Quest Diagnostics on biomarker identification of currently undetected “2+0” SMA carriers following the Milestone program signed in 2018. A first Milestone (1a) was reached at the end of 2017, resulting in the design and validation of a new GMC covering with higher precision the complex SMA region. The goal of the second Milestone (1b) consisted in performing complementary experiments and analysis on existing samples in order to identify smaller biomarkers for SMN1 cis-duplication potentially leading to SMA diagnostic test.